Business Context and Reporting Period
Company: Gilead Sciences, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2005
Business Overview: Gilead is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutics for life-threatening infectious diseases. Key products include HIV treatments (Viread, Truvada, Emtriva), Hepatitis B treatment (Hepsera), and antifungal therapy (AmBisome). The company also earns royalties from partners such as Roche (Tamiflu) and Eyetech (Macugen).
Key Financial Metrics
| Metric | Three Months Ended June 30, 2005 | Six Months Ended June 30, 2005 |
|---|---|---|
| Total Revenues | $495.3 million | $925.7 million |
| Net Income | $196.0 million | $353.1 million |
| Diluted EPS | $0.41 | $0.75 |
| Operating Cash Flow | $291.6 million (Q2 only) | $518.9 million (YTD) |
| Cash & Marketable Securities | $1.79 billion (Balance Sheet) | N/A |
| Product Gross Margin | 86% | 86% |
| Long-Term Debt | $0.3 million | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 55% year-over-year for the quarter and 47% for the six-month period. Product sales rose 50% in Q2, driven primarily by a 61% increase in HIV product sales.
- Product Performance:
- Truvada: Generated $123.1 million in Q2 sales (new product, no prior year comparison), representing over 50% of U.S. HIV sales.
- Viread: Sales increased 6% in Q2 to $209.1 million, driven by European volume growth despite a 14% volume decrease in the U.S. due to patient switching to Truvada.
- Hepsera: Sales surged 64% in Q2 to $45.8 million, largely due to a 95% volume increase in Europe.
- Royalty Revenue: Royalty and contract revenue jumped 129% in Q2 to $46.8 million, primarily due to $36.0 million in royalties from Roche for Tamiflu sales in Q1 2005 (recognized in Q2) and a $7.0 million milestone from Eyetech.
- Profitability: Net income increased 76% in Q2 and 56% YTD compared to 2004. Operating income rose 75% in Q2.
- Expenses: R&D expenses increased 31% in Q2, partly due to a $15.0 million upfront license fee for an HIV integrase inhibitor from Japan Tobacco. SG&A expenses increased 29% due to higher headcount and marketing activities.
Guidance, Outlook, and Risks
Management Commentary and Guidance
- 2005 Revenue Outlook:
- HIV Products: $1.275 billion to $1.325 billion.
- AmBisome: $205 million to $215 million.
- Hepsera: $160 million to $180 million (adjusted for new competition).
- 2005 Expense Outlook:
- R&D: $265 million to $285 million (includes a $15.0 million one-time payment to Emory).
- SG&A: $365 million to $385 million (includes European headquarters relocation costs).
- Capital Expenditures: Expected to be $55 million to $65 million for the full year.
Significant Risks and Contingencies
- Roche Dispute: Gilead delivered a notice of termination to Roche on June 23, 2005, citing material breach of the Tamiflu agreement, including an alleged $18.2 million underpayment of royalties for 2001-2003. The outcome of potential arbitration is uncertain.
- Emory Royalty Buyout: Subsequent to the quarter end (July 21, 2005), Gilead and Royalty Pharma paid $525.0 million to Emory University to buy out future emtricitabine royalties. Gilead's share ($341.3 million) will be capitalized and amortized to cost of goods sold.
- European Relocation: Relocation of European headquarters from Paris to London is expected to cost $10 million to $13 million, primarily expensed in the second half of 2005.
- Accounting Changes: Gilead expects to adopt SFAS 123R (Share-Based Payment) on January 1, 2006, which will materially impact reported earnings and cash flows.
- Competition: Increased competition noted for Hepsera (BMS's Baraclude) and AmBisome (Merck and Pfizer products).
Investor Verification Checklist
- Roche Termination Status: Verify the current status of the dispute with Roche regarding Tamiflu royalties and the potential impact on future royalty streams.
- Emory Buyout Impact: Confirm the amortization schedule for the $341.3 million Emory royalty buyout and its effect on future gross margins.
- Truvada Market Share: Monitor prescription data to ensure Truvada continues to capture market share from Viread and competitors as projected.
- European Currency Exposure: Assess the impact of foreign exchange fluctuations on reported revenues, given significant European sales.
- Relocation Costs: Track the actual costs incurred for the European headquarters relocation against the $10-$13 million estimate.